Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)J. Clin. Oncol 2020 Oct 27;[EPub Ahead of Print], RR McKay, BA McGregor, W Xie, DA Braun, X Wei, CE Kyriakopoulos, Y Zakharia, BL Maughan, TL Rose, WM Stadler, DF McDermott, LC Harshman, TK Choueiri
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.